you see this is where your story gets murky…. AML 40% response rate it is not better than doxo
will it help doxo in cancer? Yet to be seen in humans…. As you know it is a very different scenario than in vitro…. Maybe the new mice developed by a American university will help with that in the future
https://www.news-medical.net/news/20240705/Breakthrough-humanized-mouse-model-offers-new-insights-for-immunotherapy-development.aspx
Enormous history and yet in phase 1…. AGIAN and that’s the facts right now!
Trial data is the key to reveal all….
So the same AML and solid tumour are so alike why are they so hard to treat since “it is the same action” you see you say all these things but the pure evidence shows they are having a much harder time treating solid tumours than Blood cancers…. It’s exactly like saying it works in the mouse models as it has the same action so it will work in humans
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-342
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |